Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.45 |
| ▸ | ECE1 | P42892 | 6/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153567 | 0.88 | ECE1 (0.48) | F10ECE1MAOBCCR2PTGDR2 | |
| SCHEMBL3153583 | 0.86 | ECE1 (0.48) | F10ECE1MAOBCCR2PTGDR2 | |
| SCHEMBL1052362 | 0.83 | NPC1 (0.46) | F10ECE1MAOBCCR2PTGDR2 | |
| SCHEMBL1053172 | 0.83 | F10 (0.45) | F10ECE1MAOBCCR2PTGDR2 | |
| SCHEMBL1053385 | 0.83 | F10 (0.46) | F10ECE1MAOBCCR2PTGDR2 | |
| SCHEMBL927456 | 0.83 | TNIK (0.53) | F10ECE1MAOBCCR2 | |
| SCHEMBL1049577 | 0.83 | NPC1 (0.48) | F10ECE1MAOBCCR2 | |
| SCHEMBL926597 | 0.81 | F10 (0.44) | F10ECE1MAOBCCR2 | |
| SCHEMBL1051409 | 0.81 | F10 (0.44) | F10ECE1MAOBCCR2 | |
| SCHEMBL4145734 | 0.81 | F10 (0.46) | F10ECE1GRIN1GRIN2BMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235014-B1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-10-09 | — | — | EP | claimed |
| US-8299114-B2 | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2012-10-30 | — | — | US | claimed |
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-8604050-B2 | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-12-10 | — | — | US | disclosed |
| EP-2235014-B1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-10-09 | — | — | EP | disclosed |
| US-8299114-B2 | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20120252837-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-10-04 | — | — | US | disclosed |
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, HDAC1 | F10 1624/4885ECE1 3289/4885GRIN1 986/4885 |
| US-20120252837-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, HDAC1 | F10 1624/4885ECE1 3289/4885GRIN1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.